Tofenacin
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Trade names | Elamol, Tofacine, Tofalin |
| Other names | tofenacin hydrochloride (USAN US) |
| Routes of administration |
By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.035.746 |
| Chemical and physical data | |
| Formula | C17H21NO |
| Molar mass | 255.361 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma). It acts as a serotonin-norepinephrine reuptake inhibitor, and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.
See also
| |||||||||||||||||||||
| |||||||||||||||||||||
|
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||